An analyst upgrade sent share of the drugmaker higher today.
News & Analysis: Aegerion Pharmaceuticals
Competitive threats to Aegerion's flagship medicine sent shares spiraling downward in November.
New drug launches are beginning to dent demand for the company's top selling medication.
Companies are rolling out cardiovascular drugs in a bid to tap into a massive and growing market, but not every one of these companies belongs in investor portfolios.
New competitors could derail two biotech companies, while sluggish sales could imperil another.
With Aegerion Pharmaceuticals down huge from its all-time high, the current CEO's tenure is trying investors' patience.
Our Motley Fool contributors think these three stocks could have the same risks of a lottery ticket.
Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?
Soros Fund Management opened a position in the struggling biotech Aegerion Pharmaceuticals in the third quarter, even while the drugmaker's revenue estimates continued to plummet. Should retail investors follow his lead into this beaten down biotech?
Aegerion Pharmaceuticals is October's worst biotech stock after reporting weaker-than-expected third-quarter results. Find out whether this dip is a buying opportunity or a warning sign of more weakness to come.